Improving Flexibility and Quality of Life for Your Patients: A Must?

European Urology, Supplements

Volumn 8, Issue 12, 2009, Pages 857-862

  Heidenreich, Axel ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Androgen deprivation therapy; Clinical practice; Communication; Prostate cancer; Quality of life; Tolerability

Indexed keywords

CYPROTERONE ACETATE; DIETHYLSTILBESTROL; GABAPENTIN; LEUPRORELIN; MEGESTROL ACETATE; TOREMIFENE;

ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; ERECTILE DYSFUNCTION; EXPECTATION; FATIGUE; FEMUR NECK; HOT FLUSH; HUMAN; LIBIDO DISORDER; LIPID METABOLISM; LUMBAR SPINE; MENTAL DISEASE; MENTAL INSTABILITY; METABOLIC SYNDROME X; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING; WELLBEING;

EID: 71149117149     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.09.004     Document Type: Review

References (26)

1. Huggins C., Stevens R., and Hodges C.V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
2. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
3. Potosky A.L., Reeve B.B., Clegg L.X., et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94 (2002) 430-437
4. Sartor O. Counselling the prostate cancer patient. Eur Urol Suppl 7 (2008) 765-771
5. Epstein RM, Street Jr RL. Patient-centered communication in cancer care: promoting healing and reducing suffering. National Cancer Institute Web site. http://outcomes.cancer.gov/areas/pcc/communication/monograph.html. Updated February 26, 2009. Accessed March 2009.
6. Epstein R.M., Franks P., Fiscella K., et al. Measuring patient-centered communication in patient-physician consultations: theoretical and practical issues. Soc Sci Med 61 (2005) 1516-1528
7. Isbarn H., Boccon-Gibod L., Carroll P.R., et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 55 (2009) 62-75
8. Gomella L.G. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 99 Suppl 1 (2007) 25-29
9. Mottet N., Prayer-Galetti T., Hammerer P., Kattan M.W., and Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 98 (2006) 20-27
10. Holzbeierlein J.M. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 33 (2006) 181-190
11. Smith M.R., Lee H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91 (2006) 1305-1308
12. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
13. Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., and Litwin M.S. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
14. Tsai H.K., D'Amico A.V., Sadetsky N., Chen M.H., and Carroll P.R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
15. Bolla M., Collette L., van Tienhoven G., et al. Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study [abstract 65]. Int J Radiat Oncol Biol Phys 72 Suppl (2008) S30-S31
16. Nelson C.J., Lee J.S., Gamboa M.C., and Roth A.J. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 113 (2008) 1097-1106
17. Moyad M.A. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 23 (2005) 56-64
18. Diamond T.H., Higano C.S., Smith M.R., Guise T.A., and Singer F.R. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100 (2004) 892-899
19. Loprinzi C.L., Dueck A.C., Khoyratty B.S., et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 20 (2009) 542-549
20. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179 (2008) 152-155
21. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 26 (2008) 1824-1829
22. Berges R. New trends in managing the prostate cancer patient. Eur Urol Suppl 7 (2008) 758-764
23. Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 100 Suppl 1 (2007) 6-11
24. Chu F.M., Jayson M., Dineen M.K., Perez R., Harkaway R., and Tyler R.C. A clinical study of 22.5 mg. LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 168 (2002) 1199-1203
25. Perez-Marrero R., Chu F.M., Gleason D., Loizides E., Wachs B., and Tyler R.C. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 24 (2002) 1902-1914
26. Crawford E.D., Sartor O., Chu F., Perez R., Karlin G., and Garrett J.S. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 175 (2006) 533-536